Platelet activation by collagen is increased in retinal vein occlusion

Thrombosis and Haemostasis

Volumn 97, Issue 2, 2007, Pages 218-227

  Leoncini, Giuliana ^a   Bruzzese, Debora ^a   Signorello, Maria Grazia ^a   Armani, Ugo ^a   Piana, Antonietta ^a   Ghiglione, Davidina ^a   Camicione, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Collagen; Human platelets; Retinal vein occlusion

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM ION; COLLAGEN; NITRIC OXIDE; PHOSPHOLIPASE C GAMMA2; PROTEIN KINASE C; PROTEIN KINASE SYK; PROTEIN P27; ANTITHROMBOCYTIC AGENT; CALCIUM; PHOSPHOLIPASE C GAMMA; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CALCIUM CELL LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; MALE; METABOLIC PARAMETERS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA VEIN OCCLUSION; SEX RATIO; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; BLOOD; BLOOD CLOTTING PARAMETERS; CASE CONTROL STUDY; DOSE RESPONSE; DRUG EFFECT; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; THROMBOCYTE; TIME;

ADENOSINE DIPHOSPHATE; AGED; BLOOD PLATELETS; CALCIUM; CASE-CONTROL STUDIES; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NITRIC OXIDE; PHOSPHOLIPASE C GAMMA; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROTEIN KINASE C; PROTEIN-TYROSINE KINASES; RETINAL VEIN OCCLUSION; TIME FACTORS;

EID: 33947499533     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-05-0257     Document Type: Article

References (52)

1. David R, Zangwill L, Badarna M, et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. Ophthalmologica 1988; 197: 69-74.
2. Prisco D, Marcucci R, Bertini L, et al. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med 2002; 13: 163-169.
3. Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
4. Sperduto RD, Hiller R, Chew E, et al. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion: the eye disease case-control study. Ophthalmology 1998; 105: 765-771.
5. Swart J, Reichert-Thoen JW, Suttorp-Schulten MS, et al. Diabetes mellitus: a risk factor affecting visual outcome in branch retinal vein occlusion. Eur J Ophthalmol 2003; 13: 648-652.
6. Wenzler EM, Rademakers AJ, Boers GH, et al. Hyperhomocysteinemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993; 115: 162-167.
7. Vine AK. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000; 129: 640-644.
8. Abu El-Asrar AM, Abdel Gader AG, Al-Amro SA, et al. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol 2002; 12: 495-500.
9. Adamczuk YP, Iglesias Varela ML, Martinuzzo ME, et al. Central retinal vein occlusion and thrombophilia risk factors. Blood Coagul Fibrinolysis 2002; 13: 623-626.
10. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-241.
11. Gibbins J, Asselin J, Farndale R, et al. Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. J Biol Chem 1996; 271: 18095-18099.
12. Poole A, Gibbins JM, Turner M, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16: 2333-2341.
13. Leoncini G, Maresca M, Buzzi E, et al. Platelets of patients affected with Essential Thrombocythemia are abnormal in plasma membrane and adenine nucleotide content. Eur J Haematol 1990; 44: 116-120.
14. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
15. Rotondo S, Evangelista V, Manarini S, et al. Different requirement of intracellular calcium and protein kinase C for arachidonic acid release and serotonin secretion in cathepsin G-activated platelets. Thromb Haemost 1997; 78: 919-925.
16. Green LD, Wagner DA, Glogowsky J, et al. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982; 126: 131-138.
17. Granger DL, Taintor RR, Boockvar KS, et al. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods Enzymol 1996; 268: 142-151.
18. Keely PJ, Parise LV. The alpha2beta1 integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase Cgamma2 in platelets. J Biol Chem 1996; 271: 26668-26676.
19. Blake RA, Schieven GL, Watson SP. Collagen stimulates tyrosine phosphorylation of phospholipase C-gamma 2 but not phospholipase C-gamma 1 in human platelets. FEBS Lett 1994; 353: 212-216.
20. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87: 5193-5197.
21. Leoncini G, Bruzzese D, Signorello MG. The L-arginine/NO pathway in the early phases of platelet stimulation by collagen. Biochem Pharmacol 2005; 69: 289-296.
22. Roberts DE, McNicol A, Bose R. Mechanism of collagen activation in human platelets. J Biol Chem 2004; 279: 19421-19430.
23. Leoncini G, Signorello MG, Piana A, et al. Hyperactivity and increased hydrogen peroxide formation in platelets of NIDDM patients. Thromb Res 1997; 86: 153-160.
24. Leoncini G, Bruzzese D, Signorello MG. A role for PLCγ2 in platelet activation by homocysteine. J Cell Biochem 2006 in press.
25. Beaumont PE, Kang HK. Clinical characteristics of retinal venous occlusions occurring at different sites. Br J Ophthalmol 2002; 86: 572-580.
26. Hayreh SS, Zimmerman B, McCarthy MJ et al. Systemic diseases associated with various types of retinal vein occlusions, Am J Ophthalmol 2001; 131: 61-77.
27. Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026.
28. Walsh PN, Goldberg RE, Tax RL, et al. Platelet coagulant activities and retinal vein thrombosis. Thromb Haemost 1977; 38: 399-406.
29. Watson PG, Gordon JL, Kok D, et al. Platelet aggregation study in ischemic retinal vascular disease. Trans Ophtalmol Soc UK 1971; 91: 223-230.
30. Priluck IA, Impending central venal occlusion associated with increased platelet aggregability. Ann Optalmol 1979; 11: 79-84.
31. Houtsmuller AJ, Vermeulen JACM, Klompe M, et al. The influence of ticlopidine on the natural course of the retinal venal occlusion. Agents Actions Suppl. 1984; 15: 219-229.
32. Dodson PM, Westwick J, Marks G, et al. Beta-thromboglogulin and platelet factor 4 levels in retinal vein occlusion. Br J Ophthalmol 1983; 67: 143-146.
33. Yamamoto T, Kamei M, Yokoi N et al. Comparative effect of antiplatelet therapy in retinal vein occlusion evaluated by the particle-counting method using light scattering. Am J Ophthalmol 2004; 138: 809-817
34. Cahill M, Karabatzaki M, Meleady R, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol 2000; 94: 154-157.
35. Brown BA, Marx JL, Ward TP et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002; 109: 297-290.
36. Yildirim C, Yaylali V Tatlipinar S, et al. Hyperhomocysteinemia: a risk factor for retinal vein occlusion. Ophthalmologica 2004; 218: 102-106.
37. Marcucci R, Giusti B, Betti I, et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res 2003; 110: 7-12.
38. Berman RS, Martin W. Arterial endothelial barrier dysfunction: actions of homocysteine and the hypoxanthine-xanthine oxidase free radical generating system. Br J Pharmacol 1993; 108: 920-926.
39. Chambers JC, McGregor A, Jean-Marie J, et al. Acute hyperhomocysteinaemia and endothelial dysfunction. Lancet 1998; 351: 36-37.
40. Leoncini G, Bruzzese D, Signorello MG. Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. J Thromb Haemost 2006; 4: 209-216.
41. Leoncini G, Pascale R, Signorello MG. Effects of homocysteine on 1-arginine transport and nitric oxide formation in human platelets. Eur J Clin Invest 2003; 33: 713-719.
42. Menys VC, Bhatnagar D, Mackness MI et al. Spontaneous platelet aggregation in whole blood is increased in non-insulin-dependent diabetes mellitus and in female but not male patients with primary dyslipidemia. Atherosclerosis 1995; 112: 115-122.
43. Davì G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-1774.
44. Leoncini G, Signorello MG, Piana A. et al. Hydrogen peroxide formation in platelets in patients with non-insulin dependent diabetes. Platelets 1998; 9: 213-217.
45. Fusegawa Y, Hashizume H, Okumura T et al. Hypertensive patients with carotid artery plaque exhibit increased platelet aggregability. Thromb Res 2006; 117: 615-622.
46. Loschiavo C, Valvo E, Bedogna V, et al. Effects of ketanserin administration on lipid metabolism and platelet aggregation in hypertensive patients. Int J Clin Pharmacol Ther Toxicol 1990; 28: 455-457.
47. Minuz P, Patritgnani P, Gaino S, et al. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43: 64-70.
48. Shattil SJ, Cooper RA. Membrane microviscosity and human platelet function. Biochemistry 1976; 15: 4832-4837.
49. Berlin E, Shapiro SG, Friedland M. Platelet membrane fluidity and aggregation of rabbit platelets. Atherosclerosis 1984; 2: 223-239.
50. Kowalska MA, Tuszynski GP, Capuzzi DM. Plasma lipoproteins mediate platelet adhesion. Biochem Biophys Res Commun 199; 172: 113-118.
51. Ardille NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-1124.
52. Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 180-196.